查詢結果分析
來源資料
相關文獻
- 提升血液透析病人血比容之專案
- Assessment of Serum Erythropoietin Level in Chronic Hemodialysis Patients
- A Comparison of the Pain Experience After Subcutaneous Administration of Phosphate-Buffered and Citrate-Buffered Epoetin Alfa in Hemodialysis Patients
- 降低血液透析病人血色素偏低之百分比的改善專案
- 透析患者之葉酸缺乏
- The Significance of Syphilis Serology Tests on Long-Term Hemodialysis Patients
- Watermelon Stomach--An Unusual Cause of Recurrent Upper Gastrointestinal Bleeding in a Uremic Patient Receiving Estrogen-Progesterone Therapy: Case Report
- Serum Transferrin Receptor Concentration is Not Indicative of Erythropoietic Activity in Chronic Hemodialysis Patients with Poor Response to Recombinant Human Erythropoietin
- 血液透析患者飲食習慣之調查
- 血液透析動靜脈瘻管的竊血症候群
頁籤選單縮合
題名 | 提升血液透析病人血比容之專案=Improving the Hematocrit Levels of Hemodialysis Patients |
---|---|
作者 | 唐麗芬; 莊鈺荃; 徐月惠; 盧素真; Tang, Li-fen; Chuang, Yu-chuan; Hsu, Yueh-hui; Lu, Su-chen; |
期刊 | 臺灣腎臟護理學會雜誌 |
出版日期 | 20140600 |
卷期 | 13:2 2014.06[民103.06] |
頁次 | 頁31-44 |
分類號 | 415.816 |
語文 | chi |
關鍵詞 | 血液透析; 腎性貧血; 皮下注射; Hemodialysis; Renal anemia; Subcutaneous injection; |
中文摘要 | 本專案目的:希望將血液透析病人血比容大於26%的比率提升達90%及維持目標值血比容大於33%,以改善病人貧血問題。單位於2010年1月至9月的統計資料,病人血比容大於26%的比率平均只有85.5%,低於評鑑標準;血比容大於33%的比率平均占35.8%。主要原因為紅血球生成素採靜脈注射、鐵質缺乏、透析器凝固、血液流失、營養衛教成效不佳、疾病因素,導致病人貧血。藉由更改紅血球生成素為皮下注射、修訂鐵劑管理方式、修訂血液透析結束標準技術流程、護理指導後,血液透析病人血比容大於33%的比率提升至40.6%,血比容大於26%的比率提升至90.9%,紅血球生成素本由901,530元降721,224元。 |
英文摘要 | The purpose of this project was to increase the percentage of hemodialysis patients with a hematocrit (Hct) level of over 26% to 90% and maintain a target Hct of over 33% to alleviate anemia symptoms among patients. Unit records for January through to September, 2010, showed that only 85.5% of patients had a Hct above the accreditation threshold of 26%. Furthermore, only 35.8% patients had a Hct of over 35.8% from the main causes included intravenous injection of erythropoietin (EPO), lack of iron supplements, clotting in the dialyzer, bleeding, poor diet control and underlying disease. As a result, we used subcutaneous EPO injection, adjusted iron supplements, revised standard hemodialysis protocols, and nursing guidance. At end of this study, 40.6% patients had a Hct over 33% and 90.9% patients had a Hct above 26%. Total cost of EPO also decreased from NT$ 901,530 to NT$ 721,224. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。